Citations

Clear

3138 citation(s) found for "Smith, AM".

Elevated Urine LeukotrieneE4Is Associated With Worse Objective Markers in Nasal Polyposis Patients
O’Brien, Erin K. , Smith, Alyssa J. , Barnes, Jason H. , Stokken, Janalee K., Strumpf, Andrew , Divekar, Rohit , Stokken, Janalee K. , Choby, Garret , Smith, Alyssa , Barnes, Jason , Hagan, John, O'Brien, Erin K , Carlson, Matthew L , Choby, Garret , Hagan, John, Mattos, José L. , Payne, Spencer C.

Mayo Clinic

The Laryngoscope | October 1, 2020 | Volume: 131 | Issue: 5 | Pages: 961-966

10.1002/lary.29137 | PMID 33001452 Get It

ObjectivesUrine leukotriene E4 (uLTE4) is a biomarker of leukotriene synthesis and is elevated in patients with aspirin‐exacerbated respiratory disease (AERD). It can also be useful to help delineate aspirin‐tolerant chronic rhinosinusitis with nasal polyposis (CRSwNP) patients from AERD patients. The purpose of this study is to determine if uLTE4 biomarker levels are associated with objective and subjective markers of disease severity in patients with CRSwNP.MethodsA retrospective analysis of CRSwNP patients who underwent uLTE4 testing was completed to determine the association of uLTE4 levels to markers of disease severity. uLTE4 levels, as well as presenting subjective (Sinonasal Outcome Test 22 [SNOT22] scores, asthma control test [ACT] scores) and objective data (Lund‐Mackay CT score, spirometry and lab values) were collected.ResultsAmong the 157 CRSwNP patients who met inclusion criteria, uLTE4 levels were associated with history of asthma (P< .001), aspirin sensitivity (P< .001), worse Lund‐Mackay CT scores (P= .002) and other objective markers of disease severity including serum IgE (P= .05), presenting blood eosinophil level (P< .001), and the highest recorded eosinophil level (P< .001). In subgroup analysis, associations of uLTE4 to disease markers had stronger correlations in the aspirin sensitive CRSwNP group (Rrange 0.31–0.52) than the aspirin tolerant CRSwNP group (Rrange −0.30–0.24). uLTE4 levels were not associated with subjective symptom scores (SNOT22 and ACT scores).ConclusionElevated uLTE4 biomarker levels are associated with worsened objective markers of disease severity in CRSwNP patients but not patient‐reported symptom measures.Level of Evidence3Laryngoscope, 131:961–966, 2021
Monitoring BMI Trends in a Midwest Regional Head Start Population: The Results of a Healthy Lifestyle Intervention
Miccoli, Antonela , Toussaint, Loren , Hansen, Carina , Smith, Latasha M. , Lynch, Brian , Toussaint, Loren L , Hansen, Carina K , Lynch, Brian A

Mayo Clinic

Journal of Primary Care & Community Health | September 30, 2020 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2150132720962866 | PMID 32996367 Get It

Background Childhood obesity represents a public health crisis in the United States. Thus, focusing on early childhood is crucial to modify the consequences associated with obesity. The Food and Fitness Initiative (FFI) is a community-based wellness program implemented in Northeast Iowa since 2009. FFI focuses on healthy eating and physical activity. Our aim is to describe the impact on body mass index (BMI) after implementing FFI in a Northeast Iowa Community Action Head Start (HS) population. Methods Retrospective BMI data was collected from all children attending 14 HS sites from 2012 to 2018. Children with BMI measurements during July to December of the first year in HS were included in the study. Follow-up data the second year in HS was obtained. Overweight and obesity prevalence, as well as, BMI changes between year 1 and 2 in HS were analyzed. Results Data from 1013 children were collected, 850 (84%) had qualifying BMI measurements during their first year in HS and 352 of those children (41%) had follow-up data in their second year. There was a decrease in BMI between years 1 and 2 in HS that approached statistical significance ( t = 1.83, P = .07, d = .10). There were no statistically significant changes in the percent of overweight (Wald χ 2 = .50, P = .48) or obese (Wald χ 2 = 1.71, P = .19) children between the first and second year. Conclusion The FFI wellness program can be feasibly integrated into the HS curriculum and shows promising short-term results in improving BMI, but not to a statistically significant level when evaluated over 1 year.
Aß40 displays amyloidogenic properties in the non-transgenic mouse brain but does not exacerbate Aß42 toxicity in Drosophila.
Dunton, Katie L, Ceballos‐Diaz, Carolina, Jansen‐West, Karen , Dillon, Kristy, Golde, Todd E. , Levites, Yona , Mena, Lorena de , Smith, Michael A, Martin, Jason Anthony , Cruz, Pedro E. , Rincón-Limas, Diego E. , Moore, Brenda D.

Mayo Clinic

No container title available | September 28, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-47473/v3 Get It

Abstract Background Self-assembly of the amyloid-β (Aβ) peptide into aggregates, from small oligomers to amyloid fibrils, is fundamentally linked with Alzheimer’s disease (AD). However it is clear that not all forms of Aβ are equally harmful, and that linking a specific aggregate to toxicity also depends on the assays and model systems used [1, 2]. Though a central postulate of the amyloid cascade hypothesis, there remain many gaps in our understanding regarding the links between Aβ deposition and neurodegeneration. Methods In this study, we examined familial mutations of Aβ that increase aggregation and oligomerization, E22G and DE22, and induce cerebral amyloid angiopathy, E22Q and D23N. We also investigated synthetic mutations that stabilize dimerization, S26C, and a phospho-mimetic, S8E, and non-phospho-mimetic, S8A. To that end, we utilized BRI2-Aβ fusion technology and rAAV2/1 based somatic brain transgenesis in mice to selectively express individual mutant Aβ species in vivo. In parallel we generated PhiC31-based transgenic Drosophila melanogaster expressing wild type (WT) and Aβ40 and Aβ42 mutants, fused to the Argos signal peptide to assess the extent of Aβ42-induced toxicity as well as to interrogate the combined effect of different Aβ40 and Aβ42 species.Results When expressed in the mouse brain for 6 months, Aβ42 E22G, Aβ42 E22Q/D23N, and Aβ42WT formed amyloid aggregates consisting of some diffuse material as well as cored plaques, whereas other mutants formed predominantly diffuse amyloid deposits. Moreover, while Aβ40WT showed no distinctive phenotype, Aβ40 E22G and E22Q/D23N formed unique aggregates that accumulated in mouse brains. This is the first evidence that mutant Aβ40 overexpression leads to deposition under certain conditions. Interestingly, we found that mutant Aβ42 E22G, E22Q, and S26C, but not Aβ40, were toxic to the eye of Drosophila. In contrast, flies expressing a copy of Aβ40 (WT or mutants) in addition to Aβ42WT, showed improved phenotypes, suggesting possible protective qualities for Aβ40. Conclusions These studies suggest that while some Aβ40 mutants form unique amyloid aggregates in mouse brains, they do not exacerbate Aβ42 toxicity in Drosophila, which highlights the significance of using different systems for a better understanding of AD pathogenicity and more accurate screening for new potential therapies.
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System
Sparks, Matthew A. , South, Andrew M. , Badley, Andrew D. , Baker‐Smith, Carissa M. , Bozkurt, Biykem , Cattaneo, Roberto , Crowley, Steven D. , Dell’Italia, Louis J. , Ford, Andria L. , Griendling, Kathy K. , Gurley, Susan B. , Nath, Karl A. , Rangaswami, Janani , Taylor, W. Robert , Badley, Andrew D , Baker-Smith, Carissa M , Sparks, Matthew A , Batlle, Daniel , Kasner, Scott Eric , Murray, Joseph A. , Pfeffer, Marc Alan , Garovic, Vesna D.

Mayo Clinic

Hypertension | September 28, 2020 | Volume: 76 | Issue: 5 | Pages: 1350-1367

10.1161/hypertensionaha.120.15948 | PMID 32981369 Get It

The coronavirus disease 2019 (COVID-19) pandemic is associated with significant morbidity and mortality throughout the world, predominantly due to lung and cardiovascular injury. The virus responsible for COVID-19—severe acute respiratory syndrome coronavirus 2—gains entry into host cells via ACE2 (angiotensin-converting enzyme 2). ACE2 is a primary enzyme within the key counter-regulatory pathway of the renin-angiotensin system (RAS), which acts to oppose the actions of Ang (angiotensin) II by generating Ang-(1–7) to reduce inflammation and fibrosis and mitigate end organ damage. As COVID-19 spans multiple organ systems linked to the cardiovascular system, it is imperative to understand clearly how severe acute respiratory syndrome coronavirus 2 may affect the multifaceted RAS. In addition, recognition of the role of ACE2 and the RAS in COVID-19 has renewed interest in its role in the pathophysiology of cardiovascular disease in general. We provide researchers with a framework of best practices in basic and clinical research to interrogate the RAS using appropriate methodology, especially those who are relatively new to the field. This is crucial, as there are many limitations inherent in investigating the RAS in experimental models and in humans. We discuss sound methodological approaches to quantifying enzyme content and activity (ACE, ACE2), peptides (Ang II, Ang-[1–7]), and receptors (types 1 and 2 Ang II receptors, Mas receptor). Our goal is to ensure appropriate research methodology for investigations of the RAS in patients with severe acute respiratory syndrome coronavirus 2 and COVID-19 to ensure optimal rigor and reproducibility and appropriate interpretation of results from these investigations.
Local Anesthesia Prior to Ultrasound‐Guided Hip Joint Injections: A Double‐Blind Randomized Controlled Trial of Bacteriostatic Saline versus Buffered Lidocaine
Kruse, Ryan C. , Kindle, Brett J., Wisniewski, Steve J. , Presley, James T., Smith, Jay , Sellon, Jacob L. , Wisniewski, Steve, Presley, James, Presley, James

Mayo Clinic

PM&R | September 27, 2020 | Volume: 13 | Issue: 8 | Pages: 811-818

10.1002/pmrj.12489 | PMID 32935453 Get It

BackgroundUltrasound (US)‐guided hip joint injections are commonly performed for patients with suspected or known intra‐articular hip pain. Lidocaine is a well‐established local anesthetic used prior to hip joint injections, but it is often associated with discomfort during infiltration. Bacteriostatic saline is an alternative local anesthetic that has been shown to be less painful during infiltration for superficial injections.ObjectiveTo compare infiltrative pain and anesthetic efficacy of bacteriostatic saline (0.9% benzyl alcohol) with a standard local anesthetic (buffered 1% lidocaine) used for local anesthesia prior to US‐guided intra‐articular hip corticosteroid injections.DesignDouble‐blinded, randomized controlled trial.SettingTertiary care medical center.ParticipantsSixty eight patients age 18‐80 (mean 54.8) years referred for US‐guided intra‐articular hip corticosteroid injections.InterventionPatients were randomized to receive a US‐guided hip joint corticosteroid injection using either bacteriostatic saline or buffered 1% lidocaine for preinjection local anesthesia.Main Outcome MeasuresVisual Analog Scale (VAS) for pain (0‐100) during local anesthetic infiltration as well as during the intra‐articular injection. Adverse events were also recorded.ResultsThere were no significant differences between bacteriostatic saline and buffered lidocaine with respect to pain during local anesthetic infiltration or during the subsequent intra‐articular injection. Pain VAS during local anesthetic infiltration was 13.2 (95% confidence interval [CI] 7.8, 18.5) in the bacteriostatic saline group and 14.0 (95% CI 9.4, 18.5) in the buffered 1% lidocaine group (P = .82). Furthermore, pain VAS during the intra‐articular injection was 20.7 (95% CI 14.1, 27.3) in the bacteriostatic saline group and 15.7 (95% CI 10.9, 20.3) in the buffered 1% lidocaine group (P = .57). No adverse events occurred.ConclusionsBacteriostatic saline is a safe and comparably effective alternative to buffered 1% lidocaine for local anesthesia before US‐guided hip joint injections and may be considered for subcutaneous/periarticular anesthesia during similar musculoskeletal procedures.
Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement
Simonato, Matheus , Ribeiro, Henrique Barbosa , Webb, John G. , Backer, Ole De , Villablanca, Pedro, Rihal, Charanjit S. , Eleid, Mackram F. , Kempfert, Jörg , Unbehaun, Axel , Erlebach, Magdalena , Casselman, Filip , Saia, Francesco , Ubben, Timm , Meincke, Felix , Napodano, Massimo, Codner, Pablo , Schöfer, Joachim, Pelletier, Marc , Cheung, Anson , Shuvy, Mony , Palma, José Honório , Duncan, Alison , Sinning, Jan-Malte, Arbel, Yaron , Weger, Arend de , Eltchaninoff, Hélène, Hemery, Thibault, Tchétché, Didier , Dumonteil, Nicolas, Rodés‐Cabau, Josep , Kim, Won-Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben‐Yehuda, Ori , Barbanti, Marco , Fiorina, Claudia , Thukkani, Arun K., Jones, Noah, Presbitero, Patrizia , Petronio, Anna Sonia , Champagnac, Didier , Rudolph, Tanja K. , Iadanza, Alessandro , Nombela‐Franco, Luis , Bonaros, Nikolaos , Kass, Malek , Amabile, Nicolas , Messina, Antonio , Andreas, Martin , Welsh, Robert C. , Schoels, Wolfgang , Hellig, Farrel, Windecker, Stephan , Stortecky, Stefan , Maisano, Francesco , Stone, Gregg W. , Dvir, Danny , Rihal, Charanjit, Eleid, Mackram, Nombela-Franco, Luis , Windecker, Stephan , Maisano, Francesco , De Backer, Ole , Whisenant, Brian K. , Kornowski, Ran , Guerrero, Mayra , Wijeysundera, Harindra C. , Søndergaard, Lars , Rihal, Charanjit S. , Adam, Matti , Montorfano, Matteo , Ancona, Marco , Gaia, Diego Felipe , Hildick-Smith, David , Veulemans, Verena , Sinning, Jan‐Malte, Testa, Luca , Landes, Uri , Kim, Won-Keun, Teles, Rui Campante , Mackensen, G. Burkhard , Allali, Abdelhakim , Bleiziffer, Sabine , Salizzoni, Stefano , Agrifoglio, Marco , Bruschi, Giuseppe , Chhatriwalla, Adnan K , Hirji, Sameer

Mayo Clinic

Circulation | September 25, 2020 | Volume: 143 | Issue: 2 | Pages: 104-116

10.1161/circulationaha.120.049088 | PMID 32975133 Get It

Background: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. Methods: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mm Hg and significant residual mitral regurgitation (MR) as ≥ moderate. Results: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76–996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510–1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR ( P <0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mm Hg (≥5 mm Hg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients ( P =0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P <0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P =0.02). The rates of Mitral Valve Academic Research Consortium–defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P =0.01), mostly related to having postprocedural mean gradient ≥5 mm Hg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74–12.56; P =0.002) and significant residual MR (subhazard ratio, 7.88; 95% CI, 2.88–21.53; P <0.001) were both independently associated with repeat mitral valve replacement. Conclusions: Significant residual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated with a need for repeat valve replacement. Strategies to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.
Accuracy of Ultrasound Compared to Magnetic Resonance Imaging in the Diagnosis of Thumb Ulnar Collateral Ligament Injuries
Moore, Brittany J. , Iafrate, Julia L., Kakar, Sanjeev , Wisniewski, Stephen, Murthy, Naveen S. , Smith, Jay , Wisniewski, Stephen J, Kakar, Sanjeev , Murthy, Naveen S

Mayo Clinic

Journal of Ultrasound in Medicine | September 24, 2020 | Volume: 40 | Issue: 6 | Pages: 1251-1257

10.1002/jum.15491 | PMID 32930402 Get It

This prospective case series compared the accuracy of ultrasound (US) to magnetic resonance imaging (MRI) in differentiating complete displaced (CD) thumb ulnar collateral ligament (UCL) tears from nondisplaced injuries in 10 patients with suspected traumatic thumb UCL injuries. Ultrasound identified 100% (2 of 2) of MRI‐documented CD tears, both of which were further confirmed during surgical repair. Ultrasound identified the absence of CD tears in the remaining 8 patients. Although MRI is the reference standard imaging modality for characterizing thumb UCL injuries, ultrasound should be considered an accurate, cost‐effective, and alternative imaging modality to differentiate surgical versus nonsurgical thumb UCL injuries.
Usual Interstitial Pneumonia in Contemporary Surgical Pathology Practice: Impact of International Consensus Guidelines for Idiopathic Pulmonary Fibrosis on Pathologists
Eldersveld, Jordan M. , Yi, Eunhee S. , Tazelaar, Henry D. , Larsen, Brandon T. , Kunze, Katie L. , Smith, Maxwell L. , Tazelaar, Henry D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | September 23, 2020 | Volume: 145 | Issue: 6 | Pages: 717-727

10.5858/arpa.2020-0100-oa | PMID 32965489 Get It

Context.— Idiopathic pulmonary fibrosis is a clinical syndrome characterized by the presence of usual interstitial pneumonia (UIP) radiologically and pathologically. Per consensus criteria adopted in 2011, diagnosis of idiopathic pulmonary fibrosis no longer requires a biopsy in an appropriate context if UIP is seen on imaging. As a result, lung biopsies are now typically reserved for patients having indeterminate clinical or imaging findings or suspicion for alternative diagnoses, but the impact of updated guidelines on pathology practice remains unclear. Objective.— To determine the frequency of histologic UIP before and after 2011. Design.— Surgical lung biopsies from adults were studied within two 4-year periods: July 1, 2006 through June 30, 2010 and January 1, 2012 through December 31, 2015. Pathology slides were reviewed in a fashion blinded to clinical information and were classified using current guidelines. Results.— Biopsies from 177 and 86 patients (mean [SD] age, 62 [12] and 59 [14] years; 50.3% [89 of 177] and 48.8% [42 of 86] men) before and after 2011, respectively, were reviewed. Probable UIP or UIP was less-frequently encountered after 2011 in all patients with fibrosis (9 of 54 [16.7%] versus 41 of 119 [34.5%] before 2011, P = .02) and also in patients 50 years old and older (8 of 46 [17.4%] versus 39 of 109 [35.8%] before 2011, P = .02), with a concomitant rise in cases indeterminate for UIP or showing alternative diagnoses. Conclusions.— Histology for UIP is less frequently encountered in our contemporary practice compared with the historic era. The pretest probability of a non-UIP diagnosis is now high, even in elderly patients, underscoring the need for pathologists to be familiar with the histologic features of alternative diagnoses.
Occipital-Cervical Fusion and Ventral Decompression in the Surgical Management of Chiari-1 Malformation and Syringomyelia: Analysis of Data From the Park-Reeves Syringomyelia Research Consortium
CreveCoeur, Travis S. , Yahanda, Alexander T. , Maher, Cormac O. , Johnson, Gabrielle W. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Phillipp R, Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa , Bauer, David F. , Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Daniels, David, Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Jea, Andrew, Johnston, James M. , Keating, Robert F., Kelly, Michael P. , Khan, Nickalus R. , Krieger, Mark D., Leonard, Jeffrey R. , Mangano, Francesco T. , Mapstone, Timothy B., McComb, J. Gordon , Muhlbauer, Michael S., Oakes, W. Jerry, Olavarria, Greg, O’Neill, Brent R., Park, Tae Sung, Ragheb, John , Shannon, Chevis N. , Smith, Jodi L. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Kelly, Michael P , Yahanda, Alexander T , Ahmed, Raheel , Aldana, Phillip R., Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J, Haller, Gabe , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Neurosurgery | September 22, 2020 | Volume: 88 | Issue: 2 | Pages: 332-341

10.1093/neuros/nyaa460 | PMID 33313928 Get It

Abstract BACKGROUND Occipital-cervical fusion (OCF) and ventral decompression (VD) may be used in the treatment of pediatric Chiari-1 malformation (CM-1) with syringomyelia (SM) as adjuncts to posterior fossa decompression (PFD) for complex craniovertebral junction pathology. OBJECTIVE To examine factors influencing the use of OCF and OCF/VD in a multicenter cohort of pediatric CM-1 and SM subjects treated with PFD. METHODS The Park-Reeves Syringomyelia Research Consortium registry was used to examine 637 subjects with cerebellar tonsillar ectopia ≥ 5 mm, syrinx diameter ≥ 3 mm, and at least 1 yr of follow-up after their index PFD. Comparisons were made between subjects who received PFD alone and those with PFD + OCF or PFD + OCF/VD. RESULTS All 637 patients underwent PFD, 505 (79.2%) with and 132 (20.8%) without duraplasty. A total of 12 subjects went on to have OCF at some point in their management (PFD + OCF), whereas 4 had OCF and VD (PFD + OCF/VD). Of those with complete data, a history of platybasia (3/10, P = .011), Klippel-Feil (2/10, P = .015), and basilar invagination (3/12, P < .001) were increased within the OCF group, whereas only basilar invagination (1/4, P < .001) was increased in the OCF/VD group. Clivo-axial angle (CXA) was significantly lower for both OCF (128.8 ± 15.3°, P = .008) and OCF/VD (115.0 ± 11.6°, P = .025) groups when compared to PFD-only group (145.3 ± 12.7°). pB-C2 did not differ among groups. CONCLUSION Although PFD alone is adequate for treating the vast majority of CM-1/SM patients, OCF or OCF/VD may be occasionally utilized. Cranial base and spine pathologies and CXA may provide insight into the need for OCF and/or OCF/VD.
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncolog
Geller, James I. , Pressey, Joseph G. , Smith, Malcolm A. , Kudgus, Rachel A. , Cajaiba, Mariana M. , Barkauskas, Donald A. , Voss, Stephen D., Dome, Jeffrey S. , Fox, Elizabeth , Weigel, Brenda J. , Reid, Joel M. , Smith, Malcolm A , Pressey, Joseph G , Hall, David , Cho, Steve Y. , Berg, Stacey L.

Mayo Clinic

Cancer | September 22, 2020 | Volume: 126 | Issue: 24 | Pages: 5303-5310

10.1002/cncr.33195 | PMID 32914879 Get It

Background Lorvotuzumab mertansine (IMGN901) is an antibody‐drug conjugate linking an antimitotic agent (DM1) to an anti‐CD56 antibody (lorvotuzumab). Preclinical efficacy has been noted in Wilms tumor, rhabdomyosarcoma, and neuroblastoma. Synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), and pleuropulmonary blastoma also express CD56. A phase 2 trial of lorvotuzumab mertansine was conducted to assess its efficacy, recommended phase 2 dose, and toxicities. Methods Eligible patients had relapsed after or progressed on standard therapy for their tumor type. Lorvotuzumab mertansine (110 mg/m 2 per dose) was administered at the adult recommended phase 2 dose intravenously on days 1 and 8 of 21‐day cycles. Dexamethasone premedication was used. Pharmacokinetic samples, peripheral blood CD56‐positive cell counts, and tumor CD56 expression were assessed. Results Sixty‐two patients enrolled. The median age was 14.3 years (range, 2.8‐29.9 years); 35 were male. Diagnoses included Wilms tumor (n = 17), rhabdomyosarcoma (n = 17), neuroblastoma (n = 12), synovial sarcoma (n = 10), MPNST (n = 5), and pleuropulmonary blastoma (n = 1). Five patients experienced 9 dose‐limiting toxicities: hyperglycemia (n = 1), colonic fistula (n = 1) with perforation (n = 1), nausea (n = 1) with vomiting (n = 1), increased alanine aminotransferase in cycle 1 (n = 2), and increased alanine aminotransferase in cycle 2 (n = 1) with increased aspartate aminotransferase (n = 1). Non–dose‐limiting toxicities (grade 3 or higher) attributed to lorvotuzumab mertansine were rare. The median values of the maximum concentration, half‐life, and area under the curve from zero to infinity for DM1 were 0.87 µg/mL, 35 hours, and 27.9 µg/mL h, respectively. Peripheral blood CD56+ leukocytes decreased by 71.9% on day 8. One patient with rhabdomyosarcoma had a partial response, and 1 patient with synovial sarcoma achieved a delayed complete response. Conclusions Lorvotuzumab mertansine (110 mg/m 2 ) is tolerated in children at the adult recommended phase 2 dose; clinical activity is limited.